about
Screening tests using serum tissue transglutaminase IgA may facilitate the identification of undiagnosed celiac disease among Japanese population.Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients.Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56- chronic lymphoproliferative disorder of NK-cells.Large vessel vasculitis developed early after allogeneic bone marrow transplant for acute erythroid leukemia.Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations.A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria.Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia.Primary gastric diffuse large B-cell lymphoma with orbital involvement: diagnostic usefulness of 18F-fluorodeoxyglucose positron emission tomography.Donor lymphocyte infusion for extranodal NK/T cell lymphoma, nasal type, relapsed after allogeneic hematopoietic SCTLate relapse of extranodal natural killer/T cell lymphoma, nasal type, after more than ten yearsBortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial[Successful treatment of X-linked sideroblastic anemia with ALAS2 R452H mutation using vitamin B6]Breakthrough Candida guilliermondii (Meyerozyma guilliermondii) fungemia after cord blood transplantation for extranodal NK-cell lymphoma with azole prophylaxis
P50
Q33754667-E9BB09D4-0FBE-4284-B128-1EF8E376B514Q36063753-FB34111A-C07E-4D3E-A2EA-4AE8D225AAFDQ40405247-4E3FB0E4-983B-42DA-8F83-0AB72D774590Q46624379-858E830F-FE55-41E4-9DE0-058D61DF18EBQ47312234-3FD4C24D-A687-4D06-8C89-169888777DDAQ48368776-B2424C1B-43B5-4F10-85B9-1A2DCB081E39Q49282674-1941DDAD-7F65-4C18-A40B-A680AB679F03Q52611211-E81739D3-AE25-465E-9CEF-46B1DA8B275FQ52650104-BDF7CAAC-CF4B-45B8-91FD-0DA620C20634Q52718168-3A9573CF-973C-4B82-9D6C-62F78EA0BF4AQ52846448-8831C70B-C4CF-4D16-B20F-58320A6717CBQ53202435-15ED3B33-2B98-4A46-BEFC-C083F257D767Q82350259-27F19852-3201-4534-810D-0E932313A583Q84839505-BBC23173-CE93-496F-BECB-61AA942FBED0Q88210578-84C73AE6-0365-4CF6-AD32-1B10A1C36212Q88618497-A6C425FD-B183-4BD1-8D59-43C8FF717ACBQ88804952-33399893-557C-4AB8-A1FD-ED81036BE600
P50
description
biomedical researcher
@en
onderzoeker
@nl
հետազոտող
@hy
name
Hideyuki Nakazawa
@ast
Hideyuki Nakazawa
@en
Hideyuki Nakazawa
@es
Hideyuki Nakazawa
@nl
Hideyuki Nakazawa
@sl
type
label
Hideyuki Nakazawa
@ast
Hideyuki Nakazawa
@en
Hideyuki Nakazawa
@es
Hideyuki Nakazawa
@nl
Hideyuki Nakazawa
@sl
prefLabel
Hideyuki Nakazawa
@ast
Hideyuki Nakazawa
@en
Hideyuki Nakazawa
@es
Hideyuki Nakazawa
@nl
Hideyuki Nakazawa
@sl
P106
P31
P496
0000-0002-6457-5052